Mylan receives a $106.7 million verdict against GlaxoSmithKline

Share with others:


Print Email Read Later

Cecil-based generic drug company Mylan Inc. today said a federal New Jersey court has returned a $106.7 million verdict for Mylan in its breach of contract lawsuit against GlaxoSmithKline.

The suit targeted Glaxo’s Paroxetine Hydrochloride Extended-release Tablets, which Mylan said violated 2007 agreements in which Mylan acquired intellectual property rights from Glaxo.

Mylan launched its generic form of the tablets in 2008.


Steve Twedt: stwedt@post-gazette.com or 412-263-1963.

Join the conversation:

Commenting policy | How to report abuse
To report inappropriate comments, abuse and/or repeat offenders, please send an email to socialmedia@post-gazette.com and include a link to the article and a copy of the comment. Your report will be reviewed in a timely manner. Thank you.
Commenting policy | How to report abuse

Advertisement
Advertisement
Advertisement

You have 2 remaining free articles this month

Try unlimited digital access

If you are an existing subscriber,
link your account for free access. Start here

You’ve reached the limit of free articles this month.

To continue unlimited reading

If you are an existing subscriber,
link your account for free access. Start here